3-氯-5-氟苯腈 | 327056-73-5

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯腈系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-5-氟苯腈
• 中文别名: 3-氯-5-氟苯甲腈；3-氟-5-氯苯腈；3-氯-5-氟苯睛
• 英文名称: 3-fluoro-5-chlorobenzonitrile
• 英文别名: 3-chloro-5-fluorobenzonitrile
• CAS: 327056-73-5
• 化学式: C₇H₃ClFN
• 分子量: 155.559
• InChiKey: GIKLRWNRBOLRDV-UHFFFAOYSA-N

物化性质

• 熔点：
  54-59 °C(lit.)
• 沸点：
  195.0±20.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)
• 闪点：
  192 °F
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S22,S24/25,S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• WGK Germany：
  3
• 海关编码：
  2926909090
• 危险标志：
  GHS07
• 危险性描述：
  H319
• 危险性防范说明：
  P305 + P351 + P338
• 储存条件：
  存储于阴凉干燥处。

SDS

Name:	3-Chloro-5-fluorobenzonitrile 98% Material Safety Data Sheet
Synonym:	None Known
CAS:	327056-73-5

Section 1 - Chemical Product MSDS Name:3-Chloro-5-fluorobenzonitrile 98% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
327056-73-5	3-Chloro-5-fluorobenzonitrile	98%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin. May be metabolized to cyanide which in turn acts by inhibiting cytochrome oxidase impairing cellular respiration.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Metabolism may release cyanide, which may result in headache, dizziness, weakness, collapse, unconsciousness and possible death.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation. May be metabolized to cyanide which in turns act by inhibiting cytochrome oxidase impairing cellular respiration.
Chronic:
Exposure to small amounts of cyanide compounds over long periods of time is reported to cause loss of appetite, headache, weakness, nausea, dizziness, and symptoms of irritation of the upper respiratory tract and eyes.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 327056-73-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 53 - 57 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H3ClFN
Molecular Weight: 155.56

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 327056-73-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Chloro-5-fluorobenzonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 327056-73-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 327056-73-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 327056-73-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

3-氯-5-氟苯腈是一种有机腈类化合物，可用作医药合成中的中间体。它可以通过1-溴-3-氯-5-氟苯作为反应原料，在两步反应中制备得到。进一步通过强碱水解，可以将其转化为3-氯-5-氟苯甲酸。

制备

在70毫升N,N-二甲基甲酰胺中，加入25.0克1-溴-3-氯-5-氟苯（120毫摩尔）、8.45克氰化锌（72毫摩尔）、235毫克[1,1’-双(二苯基膦基)二茂铁]二氯化钯(II)与二氯甲烷的1∶1复合物（1.8毫摩尔）以及3.6毫摩尔的锌粉，将混合物加热回流1小时。冷却后，反应液用乙酸乙酯稀释，并用水和盐水进行萃取。通过硅胶色谱纯化后，得到了15.9克产物（产率85%）。

反应信息

• 作为反应物：
  描述：

  3-氯-5-氟苯腈 在 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 33.0h， 生成 3-氯-5-(2-氯-5-羟基苯氧基)苯甲腈
  参考文献：
  名称：

  使用氟硫酸盐弹头共价抑制野生型 HIV-1 逆转录酶

  摘要：

  据报道，野生型 HIV-1 逆转录酶 (CRTI) 的共价抑制剂。三种源自儿茶酚二醚非核苷抑制剂 (NNRTI) 并添加氟硫酸弹头的化合物被证明可以共价修饰 HIV-RT 的 Tyr181。提供了 CRTI 与酶复合物的 X 射线晶体结构，充分证明了共价连接，并通过 ESI-TOF 质谱中适当的质量位移进行了确认。三种 CRTI 和六种非共价类似物被发现是有效的抑制剂，其体外抑制 WT RT 的 IC 50值和对 HIV-1 感染的人类 T 细胞进行细胞病变保护的 EC 50值均在 5-320 nM 范围内。

  DOI：

  10.1021/acsmedchemlett.0c00612
• 作为产物：
  描述：

  1-溴-3-氯-5-氟苯 、 氰化锌 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 锌 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.91h， 以66%的产率得到3-氯-5-氟苯腈
  参考文献：
  名称：

  WO2006/67587

  摘要：

  公开号：

文献信息

• Compounds
  申请人：Sandoz Ltd.

  公开号：US05098466A1

  公开（公告）日：1992-03-24

  Substituted semicarbazones, thiosemicarbazones and isothiosemicarbazones and salts thereof, intermediates therefor, synthesis thereof, and the use of said compounds for the control of weeds.

  取代半胍酮，硫代半胍酮和异硫代半胍酮及其盐，其中间体，其合成，以及利用这些化合物控制杂草。
• [EN] NOVEL GALACTOSIDE INHIBITOR OF GALECTINS<br/>[FR] NOUVEAU GALACTOSIDE COMME INHIBITEUR DE GALECTINES
  申请人：GALECTO BIOTECH AB

  公开号：WO2021001528A1

  公开（公告）日：2021-01-07

  The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and/or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.

  本发明涉及一种式（1）的D-半乳糖吡喃糖类化合物，其中吡喃糖环为α-D-半乳糖吡喃糖，这些化合物是高亲和力的galectin-1和/或galectin 3抑制剂，用于治疗炎症；纤维化；瘢痕形成；瘢痕增生；异常瘢痕形成；手术粘连；脓毒性休克；癌症；转移性癌症；自身免疫疾病；代谢紊乱；心脏病；心力衰竭；病理性血管生成；眼部疾病；动脉粥样硬化；代谢性疾病；糖尿病I型；糖尿病II型；胰岛素抵抗；舒张期心力衰竭；哮喘；肝脏疾病。
• Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：——

  公开号：US20030055085A1

  公开（公告）日：2003-03-20

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  本发明提供了作为代谢型谷氨酸受体拮抗剂的化合物和药物组合物，用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。
• Heterocyclic antiviral compounds
  申请人：Dunn Patrick James

  公开号：US20060025462A1

  公开（公告）日：2006-02-02

  The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R 1 , R 2 , R 3 , R 4 , R 5 , are as defined herein.

  本发明涉及一种符合式I的化合物，通过给予符合式I的化合物治疗由人类免疫缺陷病毒介导的疾病的方法，以及用于治疗由人类免疫缺陷病毒介导的疾病的药物组合物，其中R1、R2、R3、R4、R5如本文所定义。
• Non-nucleoside reverse transcriptase inhibitors
  申请人：Sweeney Zachary Kevin

  公开号：US20080249151A1

  公开（公告）日：2008-10-09

  Compounds of formula I, wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

  式I的化合物，其中R1、R2、R3、R4、R5、X、Y和Ar如本文所定义或其药学上可接受的盐，抑制HIV-1逆转录酶，并提供一种预防和治疗HIV-1感染以及治疗艾滋病和/或ARC的方法。本发明还涉及含有式I化合物的组合物，用于预防和治疗HIV-1感染以及治疗艾滋病和/或ARC。